In particular, agalsidase alfa and beta [6, 7] have been widely used for years and have been shown to be effective on the progression of Fabry nephropathy; however, recent studies showed a dose-dependent effect of agalsidase on Gb3 clearance from cells [8, 9], and the highest doses have been reported to slow the progression of nephropathy [10, 11]. Here, GLA is linked to kidney disorder.